114th Congress. 21st Century Cures Act.; 2015. https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf.

National Health Council. Glossary of Patient Engagement Terms. Published 2019. Accessed May 18. 2021. https://nationalhealthcouncil.org/glossary-of-patient-engagement-terms/.

Center for Drug Evaluation and Research. CDER patient-focused Drug Development. U.S. Food & Drug Administration.

U.S. Department of Health and Human Services - Food and Drug Administration: Center for Devices and Radiological Health and Center for Biologics Evaluation and Research. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices - Guidance for Industry and Food and Drug Administration Staff. 2017. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guida.

115th Congress. FDA Reauthorization Act of 2017.; 2017.

U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research. Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval: Guidance for Industry and Food and Drug Administration Staff. https://www.fda.gov/media/88381/download.

Institute of Medicine (US). Forum on Drug Discovery D and T. Chapter 5: enhancing Postmarket Safety Monitoring. Challenges for the FDA: the future of Drug Safety, Workshop Summary. Volume 5. National Academies; 2007.

Institute of Medicine (IOM). Public Health Effectiveness of the FDA 510(k) Clearance Process: Balancing Patient Safety and Innovation: Workshop Report.; 2010.

U.S. Department of Health & Human Services Center for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). Published September 8, 2022. Accessed July 11. 2023. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html.

Hauser RG. Here we go again–another failure of postmarketing device surveillance. N Engl J Med. 2012;366(10):873–5. https://doi.org/10.1056/NEJMp1114695.

Article  CAS  PubMed  Google Scholar 

Rising J, Moscovitch B. The Food and Drug Administration’s unique device identification system: better postmarket data on the safety and effectiveness of medical devices. JAMA Intern Med. 2014;174(11):1719–20. https://doi.org/10.1001/jamainternmed.2014.4195.

Article  PubMed  Google Scholar 

Reynolds IS, Rising JP, Coukell AJ, Paulson KH, Redberg RF. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies. JAMA Intern Med. 2014;174(11):1773–9. https://doi.org/10.1001/jamainternmed.2014.4194.

Article  PubMed  Google Scholar 

Dagenais S, Russo L, Madsen A, Webster J, Becnel L. Use of Real-World evidence to Drive Drug Development Strategy and inform clinical Trial Design. Clin Pharmacol Ther. 2022;111(1):77–89. https://doi.org/10.1002/cpt.2480.

Article  PubMed  Google Scholar 

Pappas G, Berlin J, Avila-Tang E, et al. Determining value of coordinated Registry Networks (CRNs): a case of transcatheter valve therapies. BMJ Surg Interv Health Technol. 2019;1(1):e000003. https://doi.org/10.1136/bmjsit-2019-000003.

Article  PubMed  PubMed Central  Google Scholar 

Cronenwett JL, Avila-Tang E, Beck AW, et al. Use of data from the Vascular Quality Initiative registry to support regulatory decisions yielded a high return on investment. BMJ Surg Interv Health Technol. 2020;2(1):e000039. https://doi.org/10.1136/bmjsit-2020-000039.

Article  PubMed  PubMed Central  Google Scholar 

Califf RM, Robb MA, Bindman AB, et al. Transforming evidence generation to Support Health and Health Care decisions. N Engl J Med. 2016;375(24):2395–400. https://doi.org/10.1056/NEJMsb1610128.

Article  PubMed  Google Scholar 

Orsini LS, Berger M, Crown W, et al. Value Health. 2020;23(9):1128–36. https://doi.org/10.1016/j.jval.2020.04.002. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.

Akehurst R, Murphy LA, Solà-Morales O, Cunningham D, Mestre-Ferrandiz J, de Pouvourville G. Using real-World Data in the Health Technology Assessment of Pharmaceuticals: strengths, difficulties, and a pragmatic way Forward. Value Health. 2023;26(4):11–9. https://doi.org/10.1016/j.jval.2023.01.010.

Article  PubMed  Google Scholar 

Bipartisan Policy Center. Using Real-World Evidence to Accelerate Safe and Effective Cures: Advancing Medical Innovation for a Healthier America. Published June 2016. Accessed July 11. 2023. https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2019/03/BPC-Health-Innovation-Safe-Effective-Cures.pdf.

United States Food and Drug Administration Center for Devices and Radiological Health. Examples of Real-World Evidence (RWE) Used in Medical Device Regulatory Decisions. 2021. Accessed March 7, 2023. https://www.fda.gov/news-events/fda-voices/leveraging-real-world-evidence-regulatory-submissions-medical-devices.

Sedrakyan A, Marinac-Dabic D, Campbell B, et al. Advancing the Real-World Evidence for Medical Devices through coordinated Registry Networks. BMJ Surg Interv Health Technol. 2022;4(Suppl 1):e000123. https://doi.org/10.1136/bmjsit-2021-000123.

Article  PubMed  PubMed Central  Google Scholar 

U.S Department of Health and Human Services - Office of the Assistant Secretary for Health. Bridging the PCOR Infrastructure and Technology Innovation through Coordinated Registry Networks (CRN) Community of Practice. Accessed October 4. 2020. https://aspe.hhs.gov/bridging-pcor-infrastructure-and-technology-innovation-through-coordinated-registry-networks-crn-community-practice.

U.S Department of Health and Human Services - Office of the Assistant Secretary for Health. Developing a strategically coordinated Registry Network (CRN) for women’s Health Technology. https://aspe.hhs.gov/developing-strategically-coordinated-registry-network-crn-womens-health-technology.

U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Oncology Center of Excellence (OCE). Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision- Making for Drug and Biological Products. 2021. Accessed March 7, 2023. https://www.fda.gov/media/152503/download.

United States Food and Drug Administration. Framework for FDA’s real-world evidence program. Published Online 2018:1–37. https://doi.org/10.1038/sj.bdj.2012.1047.

U.S. Department of Health and Human Services Food and Drug, Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Use of Electronic Health Record Data in Clinical Investigations - Guidance for Industry.

Food and Drug Administration. Guidance for Industry and Food and Drug Administration Staff: Evaluation of Sex-Specific Data in Medical Device Clinical Studies. US Department of Health and Human Services Food and Drug Administration. Published online 2014:26. http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm283453.htm.

Sjödin D, Parida V, Jovanovic M, Visnjic I. Value Creation and Value capture Alignment in Business Model Innovation: a process view on outcome-based business models. J Prod Innov Manage. 2020;37(2):158–83. https://doi.org/10.1111/jpim.12516.

Article  Google Scholar 

Freudenreich B, Lüdeke-Freund F, Schaltegger S. A Stakeholder Theory Perspective on Business models: Value Creation for sustainability. J Bus Ethics. 2020;166(1):3–18. https://doi.org/10.1007/s10551-019-04112-z.

Article  Google Scholar 

Duke Margolis for Health Policy. Improving Patient Subgroup Representation with Real-World Data - Real World Efficacy and Patient Subgroups. 2023. Accessed October 4, 2023. https://healthpolicy.duke.edu/sites/default/files/2023-09/Improving%20Patient%20Subgroup%20Representation%20with%20Real%20World%20Data.pdf.

Ambrose N, Amin A, Anderson B, et al. The influence of Social determinants on receiving outpatient treatment with monoclonal antibodies, Disease Risk, and effectiveness for COVID-19. J Gen Intern Med Published Online September. 2023;15. https://doi.org/10.1007/s11606-023-08324-y.

Nugent BM, Madabushi R, Buch B, et al. Heterogeneity in treatment effects across diverse populations. Pharm Stat. 2021;20(5):929–38. https://doi.org/10.1002/pst.2161.

Article  PubMed  Google Scholar 

United States Food and Drug Administration. Guidance for Industry and Food and Drug Administration Staff: Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies. 2017. Accessed March 13, 2023. https://www.fda.gov/files/medical%20devices/published/Evaluation-and-Reporting-of-Age---Race---and-Ethnicity-Specific-Data-in-Medical-Device-Clinical-Studies---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf.

Duke Margolis Center for Health Policy. Determining Real-World Data’s Fitness for Use and the Role of Reliability. 2019. https://healthpolicy.duke.edu/real-world-evidence-collaborative.

Schneeweiss S, Brown JS, Bate A, Trifirò G, Bartels DB. Clin Pharmacol Ther. 2020;107(4):827–33. https://doi.org/10.1002/cpt.1577. Choosing Among Common Data Models for Real-World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products.

United States Food and Drug Administration. Drug Development Tools: Fit-for-Purpose Initiative. https://www.fda.gov/drugs/development-approval-process-drugs/drug-development-tools-fit-purpose-initiative.

Clark LT, Watkins L, Piña IL, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44(5):148–72. https://doi.org/10.1016/j.cpcardiol.2018.11.002.

Article  PubMed  Google Scholar 

Gray DM, Nolan TS, Gregory J, Joseph JJ. Diversity in clinical trials: an opportunity and imperative for community engagement. Lancet Gastroenterol Hepatol. 2021;6(8):605–7. https://doi.org/10.1016/S2468-1253(21)00228-4.

Article  PubMed  Google Scholar 

U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Researc. Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. Published online November 2020. Accessed August 1. 2023. https://www.fda.gov/media/127712/download.

U.S. Department of Health and Human Services Food and Drug Administration, Oncology Center of Excellence, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Office of Minority Health. Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry. Draft Guidance. Published online April 2022. Accessed August 1. 2023. https://www.fda.gov/media/157635/download.

Poulose B, Avila-Tang E, Schwartzman H et al. Determining the value of the Abdominal Core Health Quality Collaborative (ACHQC) to support Regulatory decisions. JAMA Surg.

Dal Pan GJ. Monitoring the safety of medicines used off-label. Clin Pharmacol Ther. 2012;91(5):787–95. https://doi.org/10.1038/clpt.2012.24.

Article  CAS  PubMed  Google Scholar 

Van Norman GA. Off-label use vs off-label marketing of drugs. JACC Basic Transl Sci. 2023;8(2):224–33. https://doi.org/10.1016/j.jacbts.2022.12.011.

Article  PubMed  PubMed Central  Google Scholar 

Wang SV, Schneeweiss S, Initiative RCT-DUPLICATE, et al. Emulation of Randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA. 2023;329(16):1376–85. https://doi.org/10.1001/jama.2023.4221.

Article  PubMed  PubMed Central  Google Scholar 

Franklin JM, Patorno E, Desai RJ, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative. Circulation. 2021;143(10):1002–13. https://doi.org/10.1161/CIRCULATIONAHA.120.051718.

Article  PubMed  Google Scholar 

Kuehn BM, Advocates Call for FDA to Take Tougher Stance on Postmarket Safety Studies. JAMA: J Am Med Association. 2011;306(15):1639–42. https://doi.org/10.1001/jama.2011.1477.

Xu L (Leon), Zhao H, Petruzzi NC, editors. Inducing Compliance with Postmarket Studies for Drugs Under FDA’s Accelerated Approval Pathway. Manufacturing & Service Operations Management. 2021;23(1):170–190. https://doi.org/10.1287/msom.2019.0822.

U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry and FDA Staff: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data. 2013;(May):1–35. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htmhttp://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.

United States Food and Drug Administration. Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products - Guidance for Industry. Published December 2023. Accessed January 22. 2024. https://www.fda.gov/media/154449/download.

Eisenberg R. The role of the FDA in Innovation Policy. Mich Telecommunications Technol Law Rev. 2007;13(2):345–88. https://repository.law.umich.edu/cgi/viewcontent.cgi?article=1087&context=mttlr. Accessed July 11, 2023.

Google Scholar 

Pappas G, Berlin J, Avila-Tang E, et al. Determining value of coordinated Registry Networks (CRNs): a case of transcatheter valve therapies. BMJ Surg Interv Health Technol. 2019;1:e000003. https://doi.org/10.1136/bmjsit-2019-000003.

Article  PubMed  PubMed Central  Google Scholar